Two challenges in treating patients with estrogen-positive breast cancer (ER+) have been the inability to predict who will respond to standard therapies, and adverse events that cause therapy to be discontinued.
Now, an MD Anderson study has revealed new information about how the biomarkers retinoblastoma protein (Rb) and cytoplasmic cyclin E could indicate which patients will respond best to current first-line therapies. The study...
Genetic manipulation of exosomes, virus-sized particles released by all cells, may offer a new therapeutic approach to treating pancreatic...
High response rates to a pair of combination therapies point to potentially new options for a group of metastatic melanoma patients who have...
A study at MD Anderson Cancer Center has shown promise for effective treatment of therapy-resistant cancers caused by a mutation of the RAS gene that is found in many cancers. The pre-clinical study combined therapies targeting the inhibitors polyADP ribose polymerase (PARP) and mitogen-activated protein kinase (MEK). The findings were published recently in Science Translational Medicine.
Mutations in the RAS gene...
Researchers at MD Anderson Cancer Center have found that the blend of bacteria in the digestive tract of metastatic melanoma patients is associated...
Natural killer cells sound menacing, but they play a friendly role in keeping us healthy. And they might do much more in stopping...
When Jo Ann West learned she had early-stage breast cancer, her doctor suggested an inventive new treatment that involves no major surgery...
After all 13 breast cancer patients in a first-of-its-kind clinical trial responded positively to a new targeted therapy, MD Anderson researchers...
Two new clinical trials at MD Anderson are taking aim at mantle cell lymphoma – a rare form of non-Hodgkin’s lymphoma.
Most mantle...
Researchers have found that the human papillomavirus (HPV) vaccine may reduce the rate of oral HPV infections in young adults by as much as...